BACKGROUND
Almost half of the pregnancies in the United States are unintended, 1 leading to serious health consequences for women, children, and communities, 2 and costing taxpayers an estimated $21 billion dollars a year. 3 In recognition of this significant public health and economic issue, in 2011 the Institute of Medicine identified contraceptive care as a key preventive health service for women. 4 The Department of Health and Human Services subsequently required that under the Affordable Care Act (ACA), nongrandfathered plans (ie, those sold after March 2010 or older policies that have been modified since that time) cover the full range of FDAapproved contraceptive methods without patient cost-sharing beginning on or after August 1, 2012 or at the start of the next benefit year (January 2013 for most privately insured women). 5, 6 Despite some variability across method types, 6 evidence suggests that the ACA's mandate overall translated into substantial reductions in cost-sharing for women in 2013. 7, 8 Public health experts have hoped that eliminating contraceptive cost-sharing will promote increased and more effective use of prescription contraception, reducing unintended pregnancies. 9 Particular interest has been focused on long-acting reversible contraceptive (LARC) methodsintrauterine devices (IUDs) and implants-which are the most effective reversible methods available. 10 Increased use of these methods in varying populations has been associated with lower rates of unplanned pregnancy. [10] [11] [12] LARC methods have historically been associated with high initiation costs for many US women 13 and LARC has been underutilized in the United States, 14 although rates of use have been steadily, albeit slowly, increasing. [15] [16] [17] Several studies have led to optimism that reduced cost-sharing will further increase LARC use. For example, 1 study among mostly publicly insured women in St Louis showed that eliminating cost-sharing for all contraceptive methods was associated with increased patient choice of LARC methods. 18 An analysis of insurance claims demonstrated that lower levels of cost-sharing are associated with higher rates of LARC use among privately insured women across the Unites States. 19 The early impact of the ACA's contraceptive mandate on LARC use is not yet known. We sought to examine trends in LARC use after implementation of the ACA in 2013 using insurance claims data for a large cohort of women with private employer-sponsored insurance. We first examined changes in cost-sharing for LARC before and during 2013, the year after implementation of the ACA's contraceptive mandate. We then examined monthly trends in LARC uptake and performed an interrupted time series analysis to identify whether implementation of the ACA's contraceptive coverage mandate was associated with changes in previous levels of or trends in LARC use.
METHODS
We used the Truven Health MarketScan Commercial Claims and Encounters database from January 1, 2010 to December 31, 2013. The MarketScan database represents over 50 million nonretired employees and their dependents enrolled in commercial health insurance plan products sponsored by over 100 large-sized or medium-sized USbased employers. The data include monthly enrollment, inpatient and outpatient medical claims, outpatient prescription drug claims, and reimbursed amounts paid by the health plan and patient for services billed. The study protocol was considered exempt by the Harvard Medical School Institutional Review Board.
Subjects and Contraceptive Claims
In our cohort, we included women aged 18-45 with prescription drug or medical coverage who had a prescription or medical claim for a contraceptive pill, ring, patch, depot medroxyprogesterone injection, or IUD or implant insertion during 2010-2013 and at least 12 months of continuous plan enrollment. We did not include claims for emergency contraception. Eligible women also had to have at least 1 contraceptive claim that fell after 6 months of continuous enrollment; this claim was identified as the "index" claim (N = 3,638,644 women with prescription claims; N = 501,024 with medical claims), although all of a woman's contraceptive claims during the study period (before or after the "index" claim) were included in the analysis. From this cohort we excluded 150,540 women who filled >1 prescription claim for different short-acting products on the same day (although they could have multiple months' supply of a method on a single claim), as we could not differentiate between administrative errors and multiple prescriptions. We also excluded 29,619 women for whom the sum of coinsurance and copayments were negative on any prescription or medical claim because we were concerned that these were errors. Some women had both a prescription and medical claim for an IUD, as these could represent a patient receiving the device from the pharmacy and subsequently having it placed by a provider, as required by some clinics. For these women, when the prescription and medical claims occurred within 42 days of each other (n = 18,559 claims), we omitted the first claim; however, we excluded 9692 prescription claims for IUDs and implants where there was no corresponding medical claim for insertion of the IUD or implant within 6 weeks. The final cohort included 3,794,793 unique patients and 40,593,279 contraceptive claims. Our cohortbuilding process is illustrated in Figure 1 .
Key Variables Cost-Sharing for LARC
To estimate cost-sharing, we added the copayment, coinsurance, and deductible payments paid for a LARC prescription or procedure. We also performed a sensitivity analysis examining cost-sharing trends excluding deductibles. For IUDs and implants, we estimated out-of-pocket costs for a single IUD or implant placement; when a patient had both a prescription and medical claim for LARC within 42 days of each other, we totaled the cost-sharing for the prescription and medical claims (although only counted one of these claims for the purpose of assessing LARC rates). We did not include other costs associated with an office visit because noncontraceptive services might be provided at the same time as contraception. Cost-sharing amounts are presented in 2013 dollars after adjusting for inflation on the basis of the medical price index.
LARC Initiation
To identify rates of initiation of IUDs and implants among contraceptive users, for each month from 2010-2013 we identified the number of patients in our cohort with at least 1 medical or prescription claim for contraception in that month. If a patient had a claim for an IUD or implant, we counted that patient as an IUD or implant initiator in that month. If they had claims for only non-LARC methods (categorized as branded oral, generic oral, injection, patch, or ring) in that month, we considered the patient as a non-LARC user (but someone who was potentially eligible for LARC) in that month.
Independent Variables
We measured time by month for cost-related and utilization trends. Because for most plans the ACA mandate took effect on January 1, 2013, we counted that month as the intervention month and the time after that point was considered the postintervention period. We also conducted sensitivity analyses in which we counted April 2013 as the intervention month because of the likelihood of delayed awareness of the benefit, 20 as well as the possibility of delayed implementation by plans, as we noted that the proportion of LARC claims with $0 cost-sharing continued to increase throughout the first half of 2013.
Control Variables
We documented each patient's age group (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , and 36-45 y), geographic region, relationship of patient to the insured individual/employee (employee, spouse, and dependent), and health-plan type (comprehensive plan, exclusive provider organization or health maintenance organization, noncapitated or capitated/partially capitated point-of-service plan, preferred provider organization, con-sumer-driven health plan or high-deductible health plan, and unknown).
Statistical Analysis Cost-Sharing
We described yearly trends in the proportion of contraceptive claims with $0 cost-sharing, and monthly trends in the proportion of LARC insertions that entailed $0 costsharing from 2010 to 2013. We used segmented regression analysis of an interrupted time series to estimate the impact of the ACA on changes in the level and trend of rates of $0 cost-sharing for LARC, adjusting for age, region, and plan type. 21, 22 The key variables of interest were time (month, reflecting trends in $0 cost-sharing by month from January 2010 to December 2013), ACA (reflecting a change in level of $0 cost-sharing after vs. before January 1, 2013), and time after the ACA (reflecting a change in the trend by month after the ACA-from January 2013 to December 2013). To account for repeated contraceptive claims for patients over time we used generalized estimating equations with a log link and Poisson distribution. 23 We also conducted a sensitivity analysis in which we examined cost-sharing excluding deductibles.
LARC Initiation
We estimated monthly rates of LARC initiation in our cohort of contraceptive users by calculating the proportion of women initiating an IUD or implant in a given month among women with claims for any contraceptive (long-acting and shorter-acting methods) in that month. With the patient as the unit of analysis, we again used segmented regression analysis of an interrupted time series with generalized estimating equations and a log link/Poisson distribution to estimate the impact of the ACA on changes in the level and trend in LARC use beginning in January 2013 while accounting for the underlying time trend. We included the same covariates and key variables as the model predicting $0 cost-sharing. In addition, because we noted what appeared to be seasonal variation in LARC uptake (with drops in the first quarter of each year), we added dummy variables to adjust for quarter/ season. 24 Patients with short-acting contraceptive prescriptions providing >1 month's supply who received a prescription during a previous month (or patients who received a depot medroxyprogesterone injection, which lasts 3 months) would not be included in the denominator for a month in which they had drug on hand but did not have a claim. Thus, to assess the likelihood that this affected our findings, we conducted sensitivity analyses examining quarterly rather than monthly contraceptive trends. All analyses were conducted using SAS version 9.3 (SAS Institute, Carey, NC).
RESULTS
Cohort characteristics are shown in Table 1 . Among contraceptive users, the proportion who were 18-25 years of age increased from 33.7% in 2010 to 41.5% in 2013. Similarly, the proportion of women who were dependents of the insured individual rose over time. There were some differences in distribution of plan types-most notably an increase in the proportion of women on consumer-driven and highdeductible health plans (7.4% in 2010 to 13.9% in 2013). Consistent with the US population, 25 oral contraceptive pills were the most commonly used prescription contraceptive method among index claims, but the proportion of women using brand rather than generic pills declined over the 4 years. The proportion of total claims that were for LARC rose from 1% in 2010 to 1.6% in 2013 (Table 1) .
For all methods, the proportion of claims for which cost-sharing was $0, including LARC, rose substantially from 2010 to 2013. The proportion of patients paying $0 for IUDs and implants, was 36.6% and 9.3% in 2010, and 87.6% and 80.5% in 2013, respectively (Table 1 ). Figure 2 shows monthly trends in these proportions for IUDs and implants from 2010 to 2013. At the start of 2010, 2011, and 2012, the proportion of LARC insertions with $0 costsharing was lower compared with the end of the previous year and/or the following months of that year, suggestive of higher deductible payments at the start of those calendar years. Interrupted time series analysis (Table 2) demonstrated that the ACA (with January 1, 2013 as the implementation date) was associated with a significant increase in the proportion of LARC claims with $0 cost-sharing (b coefficient, 0.65; P < 0.001), as well as an increase in a monthly trend of rising proportions of claims with $0 costsharing (b coefficient, 0.004; P < 0.001). We did identify the presence of autocorrelation in this model, likely due to the deductible patterns; however, when we adjusted the model for autocorrelation, these findings did not significantly change. In our sensitivity analysis in which we excluded deductible payments from cost-sharing amounts, we did not observe the deductible-driven seasonal fluctuations in costsharing over the course of the calendar years 2010-2012; however, the results of interrupted time series analysis were similar for the model including deductibles and in the model excluding them. Figure 3 demonstrates the monthly proportions of women with contraceptive claims who had claims for LARC insertion. There was an overall rise in the monthly proportion of women initiating LARC from 2010 to 2013, with annual drops evident at the start of 2011 and 2012, perhaps mirroring higher deductible payments. Interrupted time series analysis (Table 3) , adjusting for patient characteristics and the quarter of the year of contraceptive initiation (to address seasonal trends in LARC use), confirmed a significant trend of rising LARC uptake by month over the study period (b coefficient, 0.02; P < 0.001). Implementation of the ACA in January 2013, however, was associated with a small but statistically significant decrease in this monthly trend (b coefficient, 0.004; P < 0.001). There was no significant change in the level of LARC uptake after 2013. Among women with contraceptive claims in a given month, older women were more likely than women aged 18-25 to initiate LARC, and there were some differences in LARC initiation across regions and plan types. LARC initiation was lower in the first 2 quarters of each year compared with the last quarter. Results were similar when we used quarters as the unit of time. When we used April 1, 2013 as the date of ACA implementation, there was a significant increase in the level of LARC use associated with the ACA (b coefficient, 0.06; P < 0.001; Table 3 ).
DISCUSSION
Consistent with a recent study from a single large insurance carrier, 8 our findings demonstrate that implementation of the ACA has had substantial impact on cost-sharing for LARC for women with employer-sponsored commercial insurance, in particular dramatically increasing the proportion of women with $0 cost-sharing for LARC insertions. In interrupted time series analyses adjusting for patient and plan characteristics, rates of LARC use in our population rose steadily from 2010 to 2013, consistent with findings from a national survey that has shown steady increases from 2009 to 2012. 17 Immediately after implementation of the ACA's mandate for most plans in January 2013, the proportion of commercially insured contraceptive users initiating LARC methods was not higher than what previous trends would predict. However, our sensitivity analysis suggests that by April 2013, there may have been increases in LARC uptake beyond those predicted by previous trends. Despite this possible increase in level of LARC use, the previous rate of rise in LARC rates from 2010 to 2012 appeared to slow slightly in 2013.
Overall, our findings suggest that although reduced cost-sharing associated with the ACA's mandate did not have an immediate effect on LARC use, it may be associated with increases in LARC uptake beyond the increases that would be predicted by previous trends as early as April 2013. This finding lends cautious support to studies demonstrating that reduced cost-sharing is associated with higher rates of LARC use. 19, 26 The delay in increased uptake between January and April 2013 suggested by our sensitivity analysis may have occurred because of a lag in cost-sharing decreases, as cost-sharing continued to decline throughout 2013, perhaps because of some plans' delayed implementation of the rule. The delay might also result from low initial awareness of or confusion about the benefit changes. 20 We had expected to see an increase in the previously rising trend of LARC uptake rates after the ACA mandate. The reason for the slight flattening of the trend in 2013 is not clear. Ongoing analysis in subsequent years will be imperative to understand the longer-term impact of the ACA on levels and trends in LARC use. Reductions in cost-sharing alone may not ultimately be sufficient to make LARC available to all women desiring or needing it. LARC remains unavailable on-site at many outpatient clinics, 27,28 because of insufficient numbers of providers trained, 29, 30 and administrative and financial barriers for facilities. LARC clinical protocols (eg, those requiring multiple visits for counseling and placement 31 ) may pose additional barriers to patient access. Successful projects such as the CHOICE project in St Louis, 26 an intervention to promote LARC use at Kaiser Permanente in California, 32 and a Colorado state-wide initiative to promote LARC use among low-income teens, 12 incorporated provider training, improved patient counseling, and (in Colorado's case) reductions in the up-front cost of devices to clinics, in addition to reduced patient cost-sharing. Further, even when barriers to LARC are reduced, many patients may still choose short-acting methods, whether because of misperceptions associated with LARC methods 33 or because of informed choice. It is possible that the ACA's decrease in cost-sharing for other methods of contraception make those methods relatively more appealing to women who may have considered initiating LARC. This analysis has several strengths. We used a large dataset of claims from multiple insurers, increasing the generalizability of our findings. Our use of claims data allows assessment of actual contraceptive use rather than relying on self-report as has been conducted in other studies of LARC rates. 17 Further, use of an interrupted time series analysis allows assessment of whether the ACA's contraceptive coverage mandate impacted LARC use controlling for preexisting trends.
However, our analysis has several limitations. First, we were only able to include procedures and contraceptive methods that are reimbursed by a patient's insurance; methods that were utilized but not covered at all, or obtained outside of a patient's insurance plan, are not represented in the data. Similarly, we could only examine costs for methods that were actually utilized. This could lead to underestimation of average cost-sharing for a given method (including LARC) if among certain plans that method was infrequently selected because it was prohibitively expensive. Second, we have limited information on individual patient characteristics and about the health plan's benefit design, reducing our ability to assess for confounders as well as other factors that might significantly impact cost-sharing and LARC use. This also limits our ability to determine the generalizability of our sample to the larger population of women with employer-sponsored insurance, and to analyze differential effects of the ACA on different subgroups. Third, our estimation of contraceptive rates has some limitations. As we used monthly contraceptive claims rather than individual women using contraception as the denominator, our LARC rates should not be compared with national estimates of LARC usage. 17 In addition, because of our study's eligibility criteria, women who had a LARC method placed during her first 6 months of plan enrollment would not be included in the numerator. However, we would not expect these factors to impact our assessment of trends. The final and most important limitation to our study is that our analysis represents contraceptive choice in a very early period after the ACA, when patients and providers may not yet be fully aware of and utilizing the contraceptive benefit. 20 In conclusion, this study demonstrates that the ACA has had substantial impact on cost-sharing for LARC among women with employer-sponsored insurance. Although LARC uptake did not seem to increase immediately in 2013, findings of our sensitivity analysis suggest that as of April 2013, the proportion of women initiating LARC rose beyond the level that would be predicted by previous trends. Ongoing assessment will be important to examine the impact of the policy change on contraceptive choice as women's and providers' awareness rises and as efforts to address other barriers to LARC use grow.
